ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

D. Tripathy; S. M. Tolaney; A. D. Seidman; C. K. Anders; N. K. Ibrahim; H. S. Rugo; C. J. Twelves; V. Dieras; V. Müller; A. L. Hannah; M. A. Tagliaferri; J. Cortes Castan

doi:10.1093/annonc/mdy272.350

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

D. Tripathy, S. M. Tolaney, A. D. Seidman, C. K. Anders, N. K. Ibrahim, H. S. Rugo, C. J. Twelves, V. Dieras, V. Müller, A. L. Hannah, M. A. Tagliaferri, J. Cortes Castan

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii118
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy272.350
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy272.350

Cite this

Tripathy, D., Tolaney, S. M., Seidman, A. D., Anders, C. K., Ibrahim, N. K., Rugo, H. S., Twelves, C. J., Dieras, V., Müller, V., Hannah, A. L., Tagliaferri, M. A., & Cortes Castan, J. (2018). ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii118. https://doi.org/10.1093/annonc/mdy272.350

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). / Tripathy, D.; Tolaney, S. M.; Seidman, A. D. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii118.

Research output: Contribution to journal › Article › peer-review

Tripathy, D, Tolaney, SM, Seidman, AD, Anders, CK, Ibrahim, NK, Rugo, HS, Twelves, CJ, Dieras, V, Müller, V, Hannah, AL, Tagliaferri, MA & Cortes Castan, J 2018, 'ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii118. https://doi.org/10.1093/annonc/mdy272.350

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim NK, Rugo HS et al. ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii118. doi: 10.1093/annonc/mdy272.350

Tripathy, D. ; Tolaney, S. M. ; Seidman, A. D. et al. / ATTAIN : Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii118.

@article{c71c706ae12743fb97cd8fed518f89ba,

title = "ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)",

author = "D. Tripathy and Tolaney, {S. M.} and Seidman, {A. D.} and Anders, {C. K.} and Ibrahim, {N. K.} and Rugo, {H. S.} and Twelves, {C. J.} and V. Dieras and V. M{\"u}ller and Hannah, {A. L.} and Tagliaferri, {M. A.} and {Cortes Castan}, J.",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy272.350",

language = "English (US)",

volume = "29",

pages = "viii118",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - ATTAIN

T2 - Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

AU - Tripathy, D.

AU - Tolaney, S. M.

AU - Seidman, A. D.

AU - Anders, C. K.

AU - Ibrahim, N. K.

AU - Rugo, H. S.

AU - Twelves, C. J.

AU - Dieras, V.

AU - Müller, V.

AU - Hannah, A. L.

AU - Tagliaferri, M. A.

AU - Cortes Castan, J.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081530622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081530622&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy272.350

DO - 10.1093/annonc/mdy272.350

M3 - Article

C2 - 32136147

SN - 0923-7534

VL - 29

SP - viii118

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this